JPH08508472A - ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤 - Google Patents
ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤Info
- Publication number
- JPH08508472A JPH08508472A JP6521631A JP52163194A JPH08508472A JP H08508472 A JPH08508472 A JP H08508472A JP 6521631 A JP6521631 A JP 6521631A JP 52163194 A JP52163194 A JP 52163194A JP H08508472 A JPH08508472 A JP H08508472A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- drug
- nasal
- drug according
- apomorphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ジヒドロエルゴタミン及び/又はジヒドロエルゴタミン塩、及び、シクロデ キストリン及び/又は他の糖類及び/又は糖アルコールを含んでいる鼻腔適用の ための薬剤。 2.前記ジヒドロエルゴタミン塩がメシル酸ジヒドロエルゴタミン及び/又は酒 石酸である請求項1に記載の薬剤。 3.前記シクロデキストリンが、α−又はβ−又はγ−シクロデキストリン及び /又はα−又はβ−又はγ−シクロデキストリンの誘導体ある請求項1又は2に 記載の薬剤。 4.前記シクロデキストリンが、β−シクロデキストリン及び/又は誘導体であ る請求項1乃至3のいずれかに記載の薬剤。 5.前記β−シクロデキストリンの誘導体が、置換範囲0.5〜3.0の間でメ チル化されたβ−シクロデキストリンである請求項4に記載の薬剤。 6.前記糖類が、二糖類、好ましくはラクトース及び/又は平均分子量が10, 000〜100,000の間の多糖類、更に好ましくは平均分子量が40,00 0〜70,000の間のデキストランである請求項1乃至5のいずれかに記載の 薬剤。 7.前記糖アルコールが、マンニトール及び/又はソルビトールである請求項1 乃至6のいずれかに記載の薬剤。 8.鼻腔適用の製剤形態がパウダーであり、そのパウダー粒子が直径50〜10 0ミクロンである請求項1乃至7のいずれかに記載の薬剤。 9.前記ジヒドロエルゴタミン及び/又はその塩と、シクロデキストリン及び/ 又は二糖類及び/又は多糖類及び/又は糖アルコールとの結合が含まれている請 求項1乃至8のいずれかに記載の鼻腔に適用する薬剤の調合工程。 10.鼻腔粘膜に請求項1乃至8のいずれかに記載の薬剤を投与することにより 、偏頭痛の痛みを治療する方法。 11.アポモルヒネ及び/又はアポモルヒネ塩、及びシクロデキストリン及び/ 又は他の糖類及び/又は糖アルコールを含んでいる鼻腔適用の薬剤。 12.前記アポモルヒネ塩が、アポモルヒネ塩酸塩である請求項11に記載の薬 剤。 13.前記シクロデキストリンが、α−又はβ−又はγ−シクロデキストリン及 び/又はα−又はβ−又はγ−シクロデキストリンの誘導体である請求項11又 は12に記載の薬剤。 14.前記シクロデキストリンが、β−シクロデキストリン及び/又は誘導体で ある請求項11乃至13のいずれかに記載の薬剤。 15.前記β−シクロデキストリンの誘導体が、置換範囲が0.5〜3.0の間 であるメチル化されたβ−シクロデキストリンである請求項14に記載の薬剤。 16.前記糖類が、二糖類、好ましくはラクトース、及び/又は平均分子量10 ,000〜100,000である多糖類、更に好ましくは平均分子量が40,0 00〜70,000の間であるデキストランである請求項11乃至15のいずれ かに記載の薬剤。 17.前記糖アルコールが、マンニトール及び/又はソルビトールである請求項 11乃至16のいずれかに記載の薬剤。 18.鼻腔適用の製剤形態がパウダーであり、そのパウダー粒子が直径50〜1 00ミクロンである請求項11乃至17のいずれかに記載の薬剤。 19.前記アポモルヒネ及び/又はその塩と、シクロデキストリン及び/又は二 糖類及び/又は多糖類及び/又は糖アルコールの結合が含まれている請求項11 乃至18のいずれかに記載の鼻腔に適用する薬剤の調合工程。 20.鼻腔粘膜に請求項11乃至18のいずれかに記載の薬剤を投与することに より、パーキンソン病を治療する方法。 21.モルヒネ及び/又はモルヒネ塩、及びシクロデキストリン及び/又は他の 糖類及び/又は糖アルコールを含んでいる鼻腔適用の薬剤。 22.前記モルヒネ塩が、モルヒネ塩酸塩及び/又はアセテート及び/又は硫酸 塩である請求項21に記載の薬剤。 23.前記シクロデキストリンが、α−又はβ−又はγ−シクロデキストリン及 び/又はα−又はβ−又はγ−シクロデキストリンの誘導体である請求項21又 は22に記載の薬剤。 24.前記シクロデキストリンが、β−シクロデキストリン及び/又は誘導体で ある請求項21乃至23のいずれかに記載の薬剤。 25.前記β−シクロデキストリンの誘導体が、置換範囲0.5〜3.0の間で メチル化されたβ−シクロデキストリンである請求項24に記載の薬剤。 26.前記糖類が、二糖類、好ましくはラクトース、及び/又は平均分子量10 ,000〜100,000である多糖類、更に好ましくは平均分子量が40,0 00〜70,000の間であるデキルトランである請求項21乃至25のいずれ かに記載の薬剤。 27.前記糖アルコールが、マンニトール及び/又はソルビトールである請求項 21乃至26のいずれかに記載の薬剤。 28.鼻腔適用の製剤形態がパウダーであり、そのパウダー粒子が直径50〜1 00ミクロンである請求項21乃至27のいずれかに記載の薬剤。 29.前記モルヒネ及び/又はその塩と、シクロデキストリン及び/又は二糖類 及び/又は多糖類及び/又は糖アルコールの結合が含まれている請求項21乃至 28のいずれかに記載の鼻腔に適用する薬剤の調合工程。 30.鼻腔粘膜に請求項21乃至28のいずれかに記載の薬剤を投与することに より、苦痛を和らげる方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9300299 | 1993-03-26 | ||
BE9300298A BE1006871A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met apomorfine. |
BE9300297A BE1006870A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met morfine. |
BE9300298 | 1993-03-26 | ||
BE9300297 | 1993-03-26 | ||
BE9300299A BE1006872A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met dihydroergotamine (dhe). |
PCT/EP1994/000891 WO1994022445A2 (en) | 1993-03-26 | 1994-03-18 | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004293322A Division JP2005041884A (ja) | 1993-03-26 | 2004-10-06 | 鼻内薬剤組成物およびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08508472A true JPH08508472A (ja) | 1996-09-10 |
Family
ID=27159799
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6521631A Pending JPH08508472A (ja) | 1993-03-26 | 1994-03-18 | ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤 |
JP2004293322A Pending JP2005041884A (ja) | 1993-03-26 | 2004-10-06 | 鼻内薬剤組成物およびその製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004293322A Pending JP2005041884A (ja) | 1993-03-26 | 2004-10-06 | 鼻内薬剤組成物およびその製造方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US5756483A (ja) |
EP (2) | EP0865789B1 (ja) |
JP (2) | JPH08508472A (ja) |
AT (2) | ATE241984T1 (ja) |
AU (1) | AU6428894A (ja) |
DE (2) | DE69432789T2 (ja) |
DK (2) | DK0689438T3 (ja) |
ES (2) | ES2194867T3 (ja) |
PT (2) | PT689438E (ja) |
WO (1) | WO1994022445A2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524509A (ja) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 鼻孔投与用組成物 |
JP2002501884A (ja) * | 1998-01-30 | 2002-01-22 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 点鼻用液剤 |
JP2002527459A (ja) * | 1998-10-20 | 2002-08-27 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 粘膜表面を水和する方法 |
JP2006522785A (ja) * | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | アポモルヒネを含む肺吸入用医薬組成物 |
JP2007516947A (ja) * | 2003-07-17 | 2007-06-28 | レ ラボラトワール セルヴィエ | ピリベジルの経鼻用医薬組成物 |
JP2010516646A (ja) * | 2007-01-17 | 2010-05-20 | デヴィレックス アーゲー | シクロデキストリン処方物 |
JP2010174029A (ja) * | 2002-03-19 | 2010-08-12 | Archimedes Development Ltd | 鎮痛薬 |
JP2014518285A (ja) * | 2011-07-11 | 2014-07-28 | ブリタニア・ファーマシューティカルズ・リミテッド | 活性成分としてアポモルヒネを含む、新たな治療的組成物。 |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
ATE189121T1 (de) * | 1994-04-22 | 2000-02-15 | Pentech Pharmaceuticals Inc | Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion |
US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
EP0822821A4 (en) * | 1995-04-17 | 1999-10-27 | Robert A Sanchez | COMPLEXING URUSHIOLES |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US8631796B2 (en) | 1997-04-10 | 2014-01-21 | Cookgas, L.L.C. | Laryngeal mask |
US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US6291471B1 (en) | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
US6225343B1 (en) | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
DE10084709T1 (de) * | 1999-06-16 | 2002-09-26 | Nastech Pharm Co | Pharmazeutische Formulierung und Verfahren, die intranasales Morphin umfassen |
GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
CZ20022245A3 (cs) * | 1999-12-30 | 2002-10-16 | Tap Holdings, Inc. | Orální mukózní dávkovací formy apomorfinu |
CZ20023637A3 (cs) | 2000-04-07 | 2003-02-12 | Tap Pharmaceutical Products, Inc. | Deriváty apomorfinu a způsoby jejich použití |
US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
JP2004513899A (ja) * | 2000-11-15 | 2004-05-13 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | 抗鬱薬誘発性的機能不全のアポモルヒネによる治療 |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
US20060004190A1 (en) * | 2002-03-19 | 2006-01-05 | Michael Holick | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
EP1355158A1 (de) * | 2002-04-19 | 2003-10-22 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
EP2561860B1 (en) * | 2002-05-31 | 2018-02-28 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) * | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
KR100974482B1 (ko) | 2003-03-27 | 2010-08-10 | 가부시키가이샤 바이오악티스 | 비강용 분말 약제 투약 장치 |
MXPA05010450A (es) * | 2003-03-31 | 2005-11-04 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina. |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
EP1663159A4 (en) * | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION |
US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
EP1729724A4 (en) | 2003-12-31 | 2008-07-23 | Cydex Inc | INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
WO2005088655A1 (en) * | 2004-03-12 | 2005-09-22 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A magnetoresistive medium |
JP2007534693A (ja) | 2004-04-23 | 2007-11-29 | サイデックス・インコーポレイテッド | スルホアルキルエーテルシクロデキストリンを含有するdpi製剤 |
DK1765292T3 (en) | 2004-06-12 | 2018-01-02 | Collegium Pharmaceutical Inc | ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS |
US8673360B2 (en) * | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
JP2009526619A (ja) * | 2006-02-15 | 2009-07-23 | ティカ レーケメデル アーベー | 質量減量を伴うコルチコステロイドの滅菌 |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
JP5415769B2 (ja) | 2006-12-26 | 2014-02-12 | 株式会社新日本科学 | 経鼻投与用製剤 |
MX2009008582A (es) * | 2007-02-11 | 2009-10-30 | Map Pharmaceuticals Inc | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
WO2009040595A1 (en) * | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
US8040246B2 (en) * | 2007-12-04 | 2011-10-18 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene |
WO2010131486A1 (en) * | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
WO2011013003A2 (en) * | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
BR112012014405B1 (pt) * | 2009-12-14 | 2019-05-14 | Chiesi Farmaceutici S.P.A. | Formulação de pó seco, micropartícula, cápsula para uso com um inalador de pó seco, método para preparação de uma micropartícula e uso de uma micropartícula |
TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
CA2881158A1 (en) | 2012-07-26 | 2014-01-30 | Wockhardt Limited | Pharmaceutical composition comprising diamorphine for intranasal administration |
AU2013361337A1 (en) | 2012-12-21 | 2015-07-09 | Map Pharmaceuticals, Inc. | 8'-Hydroxy-Dihydroergotamine compounds and compositions |
ES2904570T3 (es) * | 2013-09-24 | 2022-04-05 | Satsuma Pharmaceuticals Inc | Formulación de DHE intranasal para el tratamiento del dolor de cabeza |
JP6753927B2 (ja) | 2015-09-10 | 2020-09-09 | インペル ニューロファーマ インコーポレイテッド | 直列形経鼻送達デバイス |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
CA3088942C (en) * | 2018-01-05 | 2023-01-03 | Impel Neuropharma, Inc. | Intranasal delivery of dihydroergotamine by precision olfactory device |
GB2581431A (en) * | 2018-12-11 | 2020-08-19 | Satsuma Pharmaceuticals Inc | Compositions, devices, and methods for treating or preventing headaches |
EP3893877A4 (en) | 2018-12-11 | 2022-09-14 | Satsuma Pharmaceuticals, Inc. | COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE |
US11786512B2 (en) | 2019-09-23 | 2023-10-17 | Slayback Pharma Llc | Stable pharmaceutical compositions of dihydroergotamine mesylate |
WO2022009248A1 (en) * | 2020-07-07 | 2022-01-13 | Jordan University Of Science And Technology | A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof |
IT202100009857A1 (it) | 2021-04-19 | 2022-10-19 | Univ Degli Studi Di Torino | Formulazione a rilascio controllato e prolungato di apomorfina |
CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | 吗啡鼻喷剂及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
US5169849A (en) * | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
EP0094157B1 (en) * | 1982-04-30 | 1987-07-29 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its use |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
SE8904295D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Smoking substitute |
GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
EP0475482B1 (en) * | 1990-09-13 | 1994-10-05 | Akzo Nobel N.V. | Stabilized solid chemical compositions |
US5169840A (en) * | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
DE4207922A1 (de) * | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
-
1994
- 1994-03-18 AT AT94911944T patent/ATE241984T1/de active
- 1994-03-18 DE DE69432789T patent/DE69432789T2/de not_active Expired - Lifetime
- 1994-03-18 DE DE69434304T patent/DE69434304T2/de not_active Expired - Lifetime
- 1994-03-18 JP JP6521631A patent/JPH08508472A/ja active Pending
- 1994-03-18 AT AT98109002T patent/ATE290864T1/de active
- 1994-03-18 DK DK94911944T patent/DK0689438T3/da active
- 1994-03-18 AU AU64288/94A patent/AU6428894A/en not_active Abandoned
- 1994-03-18 EP EP98109002A patent/EP0865789B1/en not_active Expired - Lifetime
- 1994-03-18 EP EP94911944A patent/EP0689438B1/en not_active Expired - Lifetime
- 1994-03-18 WO PCT/EP1994/000891 patent/WO1994022445A2/en active IP Right Grant
- 1994-03-18 PT PT94911944T patent/PT689438E/pt unknown
- 1994-03-18 ES ES94911944T patent/ES2194867T3/es not_active Expired - Lifetime
- 1994-03-18 US US08/525,771 patent/US5756483A/en not_active Expired - Lifetime
- 1994-03-18 ES ES98109002T patent/ES2239369T3/es not_active Expired - Lifetime
- 1994-03-18 DK DK98109002T patent/DK0865789T3/da active
- 1994-03-18 PT PT98109002T patent/PT865789E/pt unknown
-
1998
- 1998-04-17 US US09/062,633 patent/US5942251A/en not_active Expired - Lifetime
-
2004
- 2004-10-06 JP JP2004293322A patent/JP2005041884A/ja active Pending
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524509A (ja) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 鼻孔投与用組成物 |
JP2002501884A (ja) * | 1998-01-30 | 2002-01-22 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 点鼻用液剤 |
JP2002527459A (ja) * | 1998-10-20 | 2002-08-27 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 粘膜表面を水和する方法 |
JP2010174029A (ja) * | 2002-03-19 | 2010-08-12 | Archimedes Development Ltd | 鎮痛薬 |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
JP2006522785A (ja) * | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | アポモルヒネを含む肺吸入用医薬組成物 |
JP2007516947A (ja) * | 2003-07-17 | 2007-06-28 | レ ラボラトワール セルヴィエ | ピリベジルの経鼻用医薬組成物 |
JP2010516646A (ja) * | 2007-01-17 | 2010-05-20 | デヴィレックス アーゲー | シクロデキストリン処方物 |
JP2014518285A (ja) * | 2011-07-11 | 2014-07-28 | ブリタニア・ファーマシューティカルズ・リミテッド | 活性成分としてアポモルヒネを含む、新たな治療的組成物。 |
JP2017081947A (ja) * | 2011-07-11 | 2017-05-18 | ブリタニア・ファーマシューティカルズ・リミテッドBritannia Pharmaceuticals Limited | 活性成分としてアポモルヒネを含む、新たな治療的組成物 |
Also Published As
Publication number | Publication date |
---|---|
ATE241984T1 (de) | 2003-06-15 |
WO1994022445A2 (en) | 1994-10-13 |
DK0689438T3 (da) | 2003-09-29 |
ES2194867T3 (es) | 2003-12-01 |
DE69432789T2 (de) | 2003-12-04 |
EP0865789A3 (en) | 1999-01-07 |
EP0689438B1 (en) | 2003-06-04 |
EP0865789A2 (en) | 1998-09-23 |
JP2005041884A (ja) | 2005-02-17 |
WO1994022445A3 (en) | 1995-01-05 |
DE69432789D1 (de) | 2003-07-10 |
EP0865789B1 (en) | 2005-03-16 |
US5756483A (en) | 1998-05-26 |
ES2239369T3 (es) | 2005-09-16 |
DE69434304D1 (de) | 2005-04-21 |
EP0689438A1 (en) | 1996-01-03 |
AU6428894A (en) | 1994-10-24 |
US5942251A (en) | 1999-08-24 |
DE69434304T2 (de) | 2005-12-29 |
PT689438E (pt) | 2003-10-31 |
DK0865789T3 (da) | 2005-07-18 |
ATE290864T1 (de) | 2005-04-15 |
PT865789E (pt) | 2005-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08508472A (ja) | ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤 | |
US8889176B2 (en) | Method of managing or treating pain | |
JPH11506100A (ja) | ミソプロストールの安定化された分散系 | |
CA2522115A1 (en) | A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid | |
AU2010202623A1 (en) | Pharmaceutical compositions for nasal delivery | |
AU2005212355B2 (en) | Controlled release formulations | |
JP5103018B2 (ja) | 鼻腔内投与組成物 | |
US6007834A (en) | Nasal melatonin composition | |
WO2001030391A2 (en) | Pharmaceutical composition containing midazolam | |
WO1998042333A1 (en) | Nasal melatonin composition | |
US20220401366A1 (en) | Long acting nmda antagonists | |
KR100807480B1 (ko) | 피리베딜의 경비 투여용 약제 조성물 | |
BE1006872A6 (nl) | Nasale farmaceutische preparaten met dihydroergotamine (dhe). | |
WO2023248241A1 (en) | Oral pharmaceutical composition of cyclizine or pharmaceutically acceptable salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040706 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050531 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050607 |